# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.





### AUG 0 2 2002

TECH CENTER 1600/2900 ocket No. ORT-1548

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: SCHULTZ et al.

Serial No.: 10/022,138

Art Unit: 1616

Filed

: December 13, 2001

Examiner: N/A

For

: STEROID HORMONE PRODUCTS AND METHODS FOR PREPARING

THEM

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

COPY OF PAPERS ORIGINALLY FILED

July 22, 2002 (Date of Deposit)

Joseph S. Kentoffio (Name of applicant, assignee, or Registered Representative)

July 22, 2002

(Date of Signature)

Commissioner for Patents Washington, D.C. 20231

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the aboveidentified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with $\Box$ the
first or second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in \$1.17(p).
$\square$ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
In <b>3</b> 1.97(b) above but before the mailing date of either a Final

	Action under §1.113 or a Notice of Allowance under §1.311, or
	an action that otherwise closes prosecution and that it is
, •	accompanied by one of:
	Statement in Accordance with §1.97(e)
	(attached); or
	☐ Please charge Deposit Account No. 10-0750/ /
	the fee of $$180.00$ as set forth in $$1.17(p)$ .
	☐ In accordance with <b>§</b> 1.97(d), this Information
	Disclosure Statement is being filed after the mailing date of
	either a Final Action under §1.113 or a Notice of Allowance
	under $\S 1.311$ but before the payment of the Issue Fee.
	Applicant(s) hereby petition(s) for consideration of this
	Information Disclosure Statement. Included are: Statement in
	Accordance with §1.97(e) as set forth below and the fee of
	\$180.00 as set forth in <b>§</b> 1.17(p).
	☐ Copies of each of the references listed on the
	attached Form PTO-1449 are enclosed herewith.
	Copies of references listed on the attached Form PTO-
	1449 are enclosed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
ì	If any of the foregoing publications are not
	available to the Examiner, Applicant will

endeavor to supply copies at the Examiner's request.

igties There are no listed references which are not in the
English language.
☐ The relevance of those listed references which are
not in the English language is as follows:
Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Attached are the following non-published pending
patent applications which may be deemed relevant, which are
listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1548/JSK. This form is submitted in triplicate.

Respectfully submitted,

Joseph S. Kentoffic

Reg. No. 33,189

Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-3711
DATED: July 22, 2002